New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
13:50 EDTVICL, CBMX, IPCI, BIOS, ALIMVical, CombiMatrix poised for breakouts, says
In a report on stocks with technical attributes that indicate they may be poised for a near-term breakout, TheStreet's Roberto Pedone identifies CombiMatrix (CBMX), Vical (VICL), Intellipharmaceutics (IPCI), BioScrip (BIOS) and Alimera Sciences (ALIM). Reference Link
News For VICL;CBMX;IPCI;BIOS;ALIM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
15:53 EDTALIMJames E. Flynn reports 5.58% passive stake in Alimera Sciences
Subscribe for More Information
October 16, 2014
07:23 EDTALIMIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
16:47 EDTIPCIIntellipharmaceutics reports Q3 EPS (7c), consensus (11c)
Reports Q3 revenue $1.1M, consensus $800K.
October 8, 2014
06:33 EDTVICLVical granted six U.S. patents for HSV-2 vaccines
Vical has been issued six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2, containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. The intellectual property is jointly owned by the University of Washington and Vical.
October 7, 2014
08:17 EDTCBMXCombiMatrix expects Q3 prenatal tests volume up 71%
CombiMatrix announced that it expects to report record volumes of prenatal testing in the Q3 and nine months ended September 30, 2014. Preliminary growth rates of 71% and 64% are estimated for billable prenatal tests in the Q3 and year-to-date periods, respectively, compared to the comparable periods in 2013. The Company believes the growth rate in prenatal testing, which includes both prenatal and miscarriage testing, is the result of the Company's strategic shift to focus on its prenatal molecular diagnostics testing markets, where the Company believes that chromosomal microarray analysis is becoming the standard of care. Total microarray testing volumes for the Q3 is expected to increase 24% to 1,420 billable tests performed, compared to 1,145 tests performed in the third quarter of 2013. The Company also expects to report record cash receipts for the Q3 and nine months ended September 30, which are expected to be over $2.0M and $5.4M respectively, compared to $1.5M and $4.4M, respectively, in the comparable 2013 periods. Record cash reimbursement can be attributable to increased microarray revenues coupled with increased management focus on reimbursement and collections during the past year. The Company expects to announce complete results for the quarter and conduct a conference call following the completion of its independent auditors' review.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use